Publication Cover
Nutritional Neuroscience
An International Journal on Nutrition, Diet and Nervous System
Volume 8, 2005 - Issue 1
105
Views
28
CrossRef citations to date
0
Altmetric
Articles

The brain–adipose axis: A review of involvement of molecules

&
Pages 7-20 | Published online: 05 Sep 2013

References

  • Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. 2002. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Disord 26:274–276.
  • An S, Cutler G, Zhao JJ, Huang SG, Tian H, Li W, Liang L, Rich M, Bakleh A, Du J, Chen JL, Dai K. 2001. Identification and characterization of a Melanin-concentrating hormone receptor. Proc Natl Acad Sci USA 98:7576–7581.
  • Aprath-Husmann I, Rohring K, Gottschling-Zeller H, Skurk T, Scriba D, Birgel M, Hauner H. 2001. Effects of leptin on the differentiation and metabolism of human adipocytes. Int J Obes Relat Disord 25:1465–1470.
  • Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, Kasuga M. 2003. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52:947–952.
  • Bale TL, Contarion A, Smith CW, Chan R, Cold LH, Sawebenko FE, Koob CF, Vale WW, Lee KF. 2000. Mice deficient forcorticotropin-releasing hormone receptor-2 display anxiety-like behavior and hypersensitive to stress. Nat Genet 24:410–414.
  • Banerjee RR, Rangwata SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajata MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. 2004. Regulation of fated blood glucose by resistin. Science 303:1195–1198.
  • Banks WA. 2003. Is obesity a disease of the blood-brain barrier? physiological, pathological, and evolutionary considerations. Curr Pharmacol Des 9:801–809.
  • Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke I, Morley JE. 2004. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53:1253–1260.
  • Barb CR. 1999. The brain-pituitary-adipocyte axis. J Anim Sci 77:1249–1257.
  • Bays H, Mandarino L, DeFronzo RA. 2004. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisome proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463–478.
  • Bensaid M, Gary-Bobo M, Esclangon A, Maffraud JP, Le Fur G, Oury-Donat F, Soubrie P. 2003. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908–914.
  • Bjorback C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. 1998. Identification ofSOCS-3 as a potential mediator ofcentral leptin resistance. Mol Cell 1:619–625.
  • Bluher M, Michael MD, Peroni OD, Ueki K, Carter N, Kahn BB, Kahn CR. 2002. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25–38.
  • Boston BA, Cone RD. 1996. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3–L1 cell line. Endocrinology 137:2043–2050.
  • Boden G, Shulman GI. 2002. Free fatty acids in obesity and type 2 diabetes: Definiting their role in the development of insulin resistance and ß-cell dysfunction: Eur J Clin Invest 32:14–23.
  • Borwsky BM, Durkin MM, Ogozalck K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C. 2002. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8:825–830.
  • Bradley RL, Kokkotou EG, Maratos-Flier E, Cheatham B. 2000. Melanin-concentrating hormone regulates leptin synthesis and secretion in rat adipocytes. Diabetes 49:1073–1077.
  • Bradley RL, Masfield JP, Maratos-Flier E, Cheatham B. 2002. Melanin-concentrating hormone activates signaling pathways in 3T3–L1 adipocytes. Am J Physiol Endocrinol Metab 283:E584–E592.
  • Baranowska B, Radzikoeska M, Wasilewska-Dziubinska E, Kaplinski A, Roguski K, Plonowski A. 1999. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome. Gynecol Endocrinol 13:344–351.
  • Brebner K, Hayley S, Zacharko R, Merall Z, Anisman H. 2000. Synergistic effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha: Central monoamine, corticosterone, and behavioral variations. Neuropyschopharmacology 22:566–580.
  • Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289:2066–2067.
  • Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. 2003. Regulation of adiponectin by adipose tissue-derived cyctokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285:E527–E533.
  • Bullock BP, Heller RS, Habener JF. 1996. Tissue distribution of messenger ribonucleic acid encoding the rat glucagons-like peptide-1 receptor. Endocrinology 137:2968–2978.
  • Caro JF, Kolacznski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV. 1996. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 348:159–161.
  • Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin J, Liu WS, Park J, Ellis C, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Sarau HM. 1999. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400:261–265.
  • Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. 1999. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98:409–412.
  • Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan X-M, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Goapal-Trter S, MacIntyre DE, Chen HY, Van der Ploeg LHT. 2000. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body weight. Nat Genet 26:97–102.
  • Chen Y, Hu C, Hsu CK, Zhang Q, Asnicar M, Hsiung HM, Slieker LJ, Yang DD, Helman ML, Shi Y. 2002. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 143:2469–2477.
  • Chen HY, Trumbauer ME, Chan AS, Wingarth DT, Adams JR, Frazier FG, Shan Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van de Ploeg LH, Howard AD, MacNeil DJ, Glan S. 2004. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP). Endocrinology 145: 2607–2612.
  • Choi K, Roh SG, Hong YH, Shrestha YB, Hishikawa D, Chen C, Kojima M, Kangawa K, Sasaki S. 2003. The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 144:754–759.
  • Clark JT, Kalra PS, Crowley WR, Kalra SP. 1984. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115:427–429.
  • Claycombe KJ, Xue BZ, Mynatt RL, Zemel MB, Moustaid-Moussa N. 2000. Regulation of leptin by agouti. Physiol Genomics 27:101–105.
  • Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 334:292–295.
  • Coppack SW. 2001. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356.
  • Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale WW, Gold LH. 2000. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology 141:2698–2702.
  • Coste SC, Kesterson RA, Heldwein KA, Stervens SL, Heard AD, Hollis IH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton AR, Hatton DC, Phillips TJ, Finn DA, Low MJ, Rittenberg MB, Stenzel F, Stenzel-Foor MF. 2000. Abnormal adaptation to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403–409.
  • Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassourdis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, R, Lutz B, Stalla GK, Pagotto U. 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423–431.
  • Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ. 2001. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411:480–484.
  • Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JG. 2002. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New Engl J Med 346:1623–1630.
  • Cusin I, Dryden S, Wang Q, Rohner-Jeanrenaud F, Jeanrenaud B, Williams G. 1995. Effect of sustained physiological hyperinsu- linemia on hypothalamic neuropeptide Y and NPY mRNA levels in the rat. J Neuroendocrinol 7:193–197.
  • De Courten BV, Degawa-Yamauchi M, Considine RV, Tataranni PA. 2004. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in pima Indians. Diabetes 53:1279–1284.
  • De Lecea L, KilduffTS, Peyrun C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Cautvik VT, Bartlett IIFS, Frankel WN, van den Pol AN, Bloom FE, Cautvik KM, Sutclift JG. 1998. The hypocretins; hypothalamic specific peptide with neuroexcitatory activity. Proc Nat Acad Sci USA 95:322–327.
  • Degawa-Yamaguchi M, Rovenkark JE, Juliar BE, Watson W, Karr K, Jones R, Zhu G, Considine RV. 2003. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88:5452–6566.
  • During MJ, Cao L, Zuzga DS, Francis JS, Fitsimons HL, Jiao X, Bland RJ, Klugmann M, Ganks WA, Drucker DJ, Haile CN. 2003. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9:1173–1179.
  • English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. 2002. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984–2987.
  • Erickson JC, Hollopeter G, Palmiter RD. 1996. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 274:1704–1707.
  • Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O’Rahilly S. 2003. Clinical spectrum of obesity and mutations in the melanocortin 4 rector gene. New Engl J Med 348:1085–1103.
  • Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J. 2001. The melanocortin melanocyte-stimulating hormone/ adrenocorticotropin 4–10 decreases body fat in humans. J Clin Endocrinol Metab 86:1144–1148.
  • Flier JS, Maratos-Flier E. 1998. Obesity and the hypothalamus: Novel peptides for new pathways. Cell 92:437–440.
  • Fortuno A, Rodriguez A, Gomez-Ambrosi J, Fruhbeck G, Diez J. 2003. Adipose tissue as an endocrine organ: Role of leptin and adiponectin in the pathogenesis of cardiovascular disease. J Physiol Biochem 59:51–60.
  • Fried SK, Bunkin DA, Greenberg AS. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850.
  • Friedberg M, Zoumakis E, Hiroi N, Barder T, Chrousos GP, Hochberg Z. 2003. Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 88:385–393.
  • Fruhbeck G, Aguado M, Martinez JA. 1997. In vitro lipolytic effect of leptin on mouse adipocytes: Evidence for a possible autocrine/paracrine role of leptin. Biochem Biophys Res Commun 240:590–594.
  • Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, Kawahara Y, Yamazaki M, Ogata M, Hasegawa G, Nakamura N, Yoshikawa T, Nakano K, Ohta M. 2004. Enzyme- linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339:57–63.
  • Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, Tominaga M, Sasaki H. 1993. Hypersecretion of truncated glucagons-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 10:44–49.
  • Funahashi H, Yamada S, Kageyama H, Takenoya F, Guan JL, Shioda S. 2003. Co-expression of leptin- and orexin-receptors in feeding-regulating neurons in the hypothalamic arcuate nucleus- a triple labeling study. Peptides 24:887–894.
  • Gal CS-L, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P, Pascal M, Maffrand J-P, Fur GL. 2000. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 475:150–156.
  • Gao Q, Wolfgang MJ, Naschen S, Morino K, Horvath TL, Shulman GI, Fu XY. 2004. Distribution of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermo dysregulation. Proc Nat Acad Sci USA 101:4661–4666.
  • Gatti S, Bartfal T. 1993. Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: Comparison with interleukin-1 family and interleukin-6. Brain Res 624:291–294.
  • Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl- Hartmann C, Smith KE, Vaysse P, Dirkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL. 1996. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382:168–171.
  • Gerozissis K. 2004. Brain insulin and feeding: A bi-directional communication. Eur J Pharmacol 490:59–70.
  • Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee O, Fairclough P, Bhattacharys S, Carpenter R, Grossman AB, Korbonits M. 2002. The tissue distribution of the mRNA of ghrelin and subtype of its receptor, GHS-R, in human. J Clin Endocrinol Metab 87:2991.
  • Gollins GA, Kym PR. 2003. Prospects for obesity treatment: MCH receptor antagonists. Curr Opin Invest Drugs 4:386–394.
  • Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KI. 1997. Overexpression of Agrp leads to obesity in transgenic mice. Nat Genet 17:273–274.
  • Green A, Dobias SB, Walters DJ, Brasier AR. 1994. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 134:2581–2588.
  • Haekansson ML, Brown H, Chilardi N, Skoda RC, Meister B. 1998. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J Neurosci 18:559–572.
  • Hahn TM, Breiniger JF, Baskin DG, Schwartz MW. 1998. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1:271–272.
  • Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, Arch JR. 2002. Anorectic thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 104:153–159.
  • Heinrichs SC, Menzaghi F, Pich EM, Hauger RI, Koob GF. 1993. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res 611:18–24.
  • Hill J, Duckworth M, Murdock P, Rennie G, Sabido-David C, Ames RS, Szekeres P, Wilson S, Bergsma DJ, Gloger IS, Levy DS, Chambers JK, Muir AI. 2012. Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J Biol Chem 276:5–20129.
  • Horvath TL. 2003. Endocannabinoids and the regulation of body fat: The smoke is clearing. J Clin Invest 112:323–326.
  • Horvath TL, Diano S, van den Pol NA. 1999. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: A novel circuit implicated in the metabolic and endocrine regulation. J Neurosci 19:1072–1087.
  • Hotamistigli GS, Shargill NS, Spiegelman BM. 1993. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity- linked insulin resistance. Science 259:87–91.
  • Hsu SY, Hsuch AJ. 2001. Human stresscopin and stresscopin- related peptide are selective ligands for type 2 corticotropin- releasing hormone receptor. Nat Med 7:605–611.
  • Huan JN, Han Y, Chen K, Wu N, Zhao AZ. 2003. Adipocyte- selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance. J Biol Chem 278:45838–45850.
  • Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeler LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. 1997. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131–141.
  • Igarashi N, Tastumi K, Nakamura A, Sakao S, Takiguchi Y, Ichikawa T, Kuriyama T. 2003. Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome. Chest 124:1381–1385.
  • Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. 2001. Prepro-orexin and orexin receptor mRNA are differentially expressed in peripheral tissues of male and female rats. Endocrinology 142:3324–3331.
  • Kaiyala KJ, Prigeon RL, SE, Woods SC, Schwartz MW. 2000. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49:1525–1533.
  • Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. 1999. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68–100.
  • Kanatani A, Hata M, Mashiko S, Ishihara A, Okamoto O, Haga Y, Ohe T, Kanno T, Murai N, Ishii Y, Fukuroda T, Fukami T, Ihara M. 2001. A typical Y1 receptor regulates feeding behaviors: Effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 59:501–505.
  • Kask A, Mutulis F, Muceniece R, Pahkla R, Mutule I, Wikberg JE, Rago L, Schloth HB. 1998. Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): Evaluation in vitro and in vivo. Endocrinology 139:5006–5014.
  • Kastin AJ, Akerstrom V. 1999. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 289:219–223.
  • Katsuki A, Sumida Y, Gabazza EV, Murahashi S, Tanaka T, Furuta M, Araki-Sasaki T, Hori Y, Nakatani K, Yano Y, Adachi Y. 2001. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab 86:1921–1924.
  • Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii N, Tsuchihashi K, Goto H, Nakatani K, Yano Y. 1998. Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83:859–862.
  • Katsuki A, Sumida Y, Murashima S, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Adachi Y. 2000. Elevated plasma levels of alpha-melanocyte stimulating hormone (alpha-MSH) are correlated with insulin resistance in obese men. Int J Obes Relat Metab Disord 24:1260–1264.
  • Kern PA, Ranganathan S, Ki C, Wood L, Ranganathan G. 2001. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751.
  • Kim MS, Rossi M, Abusnana S, Sunter D, Morgan DGA, Small CJ, Edwards CMB, Heath MM, Stanley SA, Seal LJ, Ghatti JR, Smith DM, Ghatei MA, Bloom SR. 2000. Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone. Diabetes 49: 177–182.
  • Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Totamisligil GS. 1997. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 100:2777–2782.
  • Kojima M, Hosoda H, Date Y, Nakazato M, Mtsuo H, Kangawa K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:658–660.
  • Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. 1998. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Nat Acad Sci USA 95:15659–15664.
  • Larsen PJ, Tang-Christensen M, Jessop D. 1997. Central administration of glucagons-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445–4455.
  • Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. 2001. Systemic administration of the long-acting GLP-1 derivative NM2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50:2530–2539.
  • Li G, Mobbs CV, Scarpace PJ. 2003. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 52:1951–1957.
  • Lindsay RS, Funahashi T, Hanson RI, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58.
  • Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RF, Wilkitson WO, Cone RD. 1994. Agouti protein is an antagonist of the melanocyte-stimulating hormone receptor. Nature 371:799–802.
  • Lu XY, Bagnil D, Burks S, Akil H, Watson SJ. 2000. Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Horm Behav 37:335–344.
  • Ludwig DS, Tritos NA, Mastaitis JW, Kulkarni R, Kokkotou E, Elmquist J, Lowell B, Flier JS, Maratos-Flier E. 2001. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 107: 379–386.
  • McTernan PG, McTernan CL, Chetty R, Jenner K, M FM, Lauer MN, Crocker J, Barnett AH, Kumar S. 2002. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407–2410.
  • Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. 2002. Diet-induced insulin resistance in mice lacking adiponencti- n/ACRP30. Nat Med 8:731–737.
  • Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. 1995. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1:1155–1161.
  • Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, Shen Z, Frazier EG, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNell DJ, Strack AM, Maclntyre DE, Van der Ploeg LH, Qian S. 2002. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Nat Acad Sci USA 99:3240–3245.
  • Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H. 2003. Peripheral, but not central, administration of adiponectin reduces visceral adiposity and regulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice. Diabetes 52:2266–2273.
  • Masaki T, Chiba S, Noguchi H, Yasuda T, Tobe K, Suzuki R, Kadowaki T, Yoshimatsu H. 2004. Obesity in insulin receptor substrate-2-deficient mice: Disrupted control of arcuate nucleus neuropeptides. Obes Res 12:878–885.
  • Masuzaki H, Paterson J, Shinyama H, Morton NM, Multins JJ, Seckl JR, Flier JS. 2001. A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166–2170.
  • Miner JL. 2004. The adipocyte as an endocrine cell. J Anim Sci 82:936–941.
  • Mohamed Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. 1999. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol Endocrinol Metab 277:E971–E975.
  • Minokoshi Y, Alquier T, Furukawa N, Kim YB, Aee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB. 2004. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569–574.
  • Morash BA, Wilkinson D, Ur E, Wilkinson M. 2002. Resistin expression and regulation in mouse pituitary. FEBS Lett 526:26–30.
  • Mynatt RL, Stephens JM. 2001. Agouti regulates adipocyte transcription factors. Am J Physiol Cell Physiol 280: C954 -C961.
  • Nagaev I, Smith U. 2001. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561–563.
  • Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. 2001. A role for ghrelin in the central regulation of feeding. Nature 409:194–198.
  • Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, Marcus C. 2001. Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J Clin Endocrinol Metab 86: 4849–4853.
  • Norman D, Isidori AM, Frajese V, Caprio M, Chew SL, Grossman AB, Clark AJ, Michael Besser G, Fabbri A. 2003. ACTH and alpha-MSH inhibit leptin expression and secretion in 3T3–L1 adipocytes: Model for a central-peripheral melanocortin-leptin pathway. Mol Cell Endocrinol 200:99–109.
  • Ohata H, Arai K, Shibasaki T. 2002. Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. European Journal of Pharmacology 457:201–206.
  • Okamoto H, Nakae J, Kitamura T, Park BC, Dragatsis I, Accili D. 2004. Transgenic rescue of insulin receptor-deficient mice. J Clin Invest 114:214–223.
  • Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsg GS. 1997. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135–138.
  • Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. 2001. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: Increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86:2281–2288.
  • Pedrazzani T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, Brunner HR. 1998. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 4:722–726.
  • Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. 2002. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet- induced obesity. Diabetes 51:1337–1345.
  • Pohl A, Nordin C. 2003. Body mass index influences plasma concentration of neuropeptide Y in healthy female volunteers: A pilot study. Gynecol Endocrinol 17:409–412.
  • Presse F, Sorokovsky I, Max JF, Nicolaidis S, Nahon JL. 1996. Melanin-concentrating hormone is a potent anorectic peptide regulated by food-deprivation and glucopenia in the rat. Neuroscience 71:735–745.
  • Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. 2004. Adiponenctin acts in the brain to decrease body weight. Nat Med 11:524–529.
  • Qian S, Chen H, Waingarth D, Trumbauer ME, Novi DE, Guan X, Yu H, Shan Z, Fang Y, Frazier E, Chen A, Camacho RE, Shearman LP, Gopal-Truter S, MacNeil DJ, Van der Ploeg LH, Marsh DJ. 2002. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 22:5027–5035.
  • Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E. 1996. A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature 380:243–247.
  • Ranganath LR, Beely JM, Morgan LM, Wright JW, Howland R, Marks V. 1996. Attenuated GLP-1 secretion in obesity: Cause or consequence? Gut 38:916–919.
  • Raposinho PD, Padrazzini T, White RB, Palmitar RD, Aubart ML. 2004. Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression. Endocrinology 145:304–310.
  • Reaven GM. 2003. Insulin resistance/compensatory hyperinsuline- mia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88:2399–2403.
  • Risk NM, Joost HG, Eckal J. 2001. Increased hypothalamic expression of the p78 tumor necrosis factor receptor in New Zealand obese mice. Horm Metab Res 33:520–524.
  • Rossi M, Choi SJ, O’Shea D, Miyoshi T, Ghatei MA, Bloom SR. 1997. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 138:351–355.
  • Ruan H, Harcohen N, Golub TR, Parijs LV, Lodish HF. 2002. Tumor necrosis factor-a suppresses adipocyte-specific genes and activates expression ofpreadipocyte genes in 3T3–L1 adipocytes: Nuclear factor-kB activation by TNF-a is obligatory. Diabetes 51:1319–1336.
  • Sahu A, Dube MG, Phelps CP, Sninsky CA, Kalra PS, Kalra SP. 1995. Insulin and insulin-like growth factor II suppress neuropeptide Y release from the nerve terminals in the paraventricular nucleus: A putative hypothalamic site for energy homeostasis. Endocrinology 136:5718–5724.
  • Sahu A, Kalra SF, Crowley WR, Kaira PS. 1988. Evidence that NPY-containing neurons in the brain stem project into selected hypothalamic nuclei: Implication in feeding behavior. Brain Res 457:376–378.
  • Sainsbury A, Scwarzer C, Couzens M, Fetissov S, Furtinger S, Jankin A, Cox HM, Sperk G, Hokfelt T, Herzog H. 2002. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Nat Acad Sci USA 99:8938–8943.
  • Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. 1999. Molecular characterization of the Melanin-concentrating hormone receptor. Nature 400:265–269.
  • Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GF, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Eishourbagy NA, Bergama DJ, Yanagisawa M. 1998. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulates feeding behavior. Cell 92:573–585.
  • Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard DE, Porte D Jr., Woods SC, Seeley RJ, Weigle DS. 1996. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 45:531–535.
  • Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide- 1 receptor gene. Nat Med 2:1254–1258.
  • Seres J, Bornstein SR, Seres P, Willenberg HS, Schutle KM, Scherbaum WA, Ehrart-Bornstein M. 2004. Corticotropin- releasing hormone system in human adipose tissue. J Clin Endocrinol Metab 89:965–970.
  • Shiiya T, Nakazato M, Mizuta M, Date Y, Mondai MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. 2002. Plasma ghrelin levels in lean and obese humans and effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240–244.
  • Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. 1998. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396:670–674.
  • Shimizu H, Shimomura Y, Hayashi R, Ohtani K, Sato N, Futawatari T, Mori M. 1997. Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 21:536–541.
  • Sindelar DR, Mystkowski P, Marsh DJ, Palmiter RD, Schwartz MW. 2002. Attenuation ofdiabetic hyperphagia in neuropeptide Y-deficient mice. Diabetes 51:778–783.
  • Smith SR, Gawronska-Kozak B, Janderova L, Nguyen T, Murrell A, Stephens JM, Mynatt RL. 2003. Agouti expression in human adipose tissue: Functional consequences and increased expression in type 2 diabetes. Diabetes 52:2014–2022.
  • Stefan N, Stumvoll M. 2002. Adiponectin–its role in metabolism and beyond. Horm Metab Res 34:469–473.
  • Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO. 2003. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/ obese subjects. J Clin Endocrinol Metab 88:4379–4383.
  • Steppan CM, Kazar MA. 2002. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13:18–23.
  • Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjec RR, Wright CM, Fatel HR, Ahima RS, Lazzar MA. 2001. The hormone resistin links to diabetes. Nature 409:307–312.
  • Stricker-Krongrad A, Dimitrov T, Beck B. 2001. Central and peripheral dysregulation of melanin-concentrating hormone in obese Zucker rats. Brain Res Mol Brain Res 92:43–48.
  • Stunkard AJ. 1996. Current views on obesity. Am J Med 100:230–236.
  • Sun Y, Ahmed S, Smith RG. 2003. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23:7973–7981.
  • Sun Y, Wang P, Zheng H, Smith RG. 2004. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Nat Acad Sci USA 101:4679–4684.
  • Switonska MM, Kaczmarek P, Malendowicz LK, Nowak KW. 2002. Orexin and adipoinsular axis function in the rat. Regul Pept 104:69–73.
  • Takahsahi K. 2004. Translational medicine in fish-derived peptides: From fish endocrinology to human physiology and diseases. Endocr J 51:1–17.
  • Tang-Christensen M, Larsen PJ, Thulesen J, Rokier J, Vrang N. 2000. The proglucagon-derived peptide, glucagons-like peptide 2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6:802–807.
  • Tassone F, Brogio F, Destefanis S, Rovere S, Benso A, Cottero C, Prodam F, Rossetto R, Gauna C, van der Lely AJ, Ghigo E, Maccario M. 2003. Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. J Clin Endocrinol Metab 88:5478–5483.
  • Tatemoto K. 1982. Neuropeptide Y: Complete amino acid sequence of the brain peptide: Proc Nat Acad Sci USA 79:5483–5489.
  • Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA, Robinson IC, Wells T. 2004. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145:234–242.
  • Thornton JE, Cheung CC, Clifton DK, Steiner RA. 1997. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 138:5063–5066.
  • Toft-Niesen M-B, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. 2001. Determinations of the impaired secretion of glucagons-like peptide-1 in type 2 diabetes patients. J Clin Endocrinol Metab 86:3717–3723.
  • Trivedi PG, Yu H, Trumbauer M, Chen H, Van der Ploeg LH, Guan X. 2001. Differential regulation of neuropeptide Y receptors in the brain of NPY knock-out mice. Peptides 22:395–403.
  • Tschoep M, Smiley DL, Heineman ML. 2000. Ghrelin induces adiposity in rodents. Nature 407:908–913.
  • Tsigos C, Papanicolaou DA, Kytou I, Defensor R, Mitstadis CS, Chrousos GF. 1997. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167–4170.
  • Tsujii S, Bray GA. 1989. Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 23:165–169.
  • Tucci SA, Rogers EK, Korbonits M, Kirkham TC. 2004. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520–523.
  • Turton MD, O’Shea D, Gunn IN, Beak SA, Edwards CM, Meeran K, Chol SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatel MA, Herbert J, Bloom SR. 1996. A role for glucagons-like peptide-1 in the central regulation of feeding. Nature 379:69–72.
  • Uehara Y, Shimizu H, Ohtani K, Sato N, Mori M. 1998. Hypothalamic corticotropin-releasing hormone is a mediator of the anorexigenic effect of leptin. Diabetes 47:890–893.
  • Uysal KT, Wiesbrock SM, Marino MW, Hotamislgii GS. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-a function. Nature 389:610–614.
  • Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakie M, Kollias G, Moller DE. 1997. Targeted disruption of the tumor necrosis factor-alpha gene: Metabolic consequences in obese and nonobese mice. Diabetes 48:1526–1531.
  • Wardlaw SL. 2001. Obesity as a neuroendocrine disease: Lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 86:1442–1446.
  • Wallenius V, Wallenius K, Ahren B, Rudling M, Gartstan H, Dickson SL, Ohlsson C, Jansson JO. 2002a. Interleukin-6- deficient mice develop mature-onset obesity. Nat Med 8:75–79.
  • Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JD. 2002b. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560–565.
  • Wang Y, Kole HK, Montrose-Rafizaden C, Perfetti R, Bernier M, Egan JM. 1997. Regulation of glucose transporters and hexose uptake in 3T3–L1 adipocytes: Glucagons-like peptide-1 and insulin interactions. J Mol Endocrinol 19:241–248.
  • Watson RT, Naknzaki M, Pessin JE. 2004. Regulated membrane trafficking of the insulin-responsive glucose transport 4 in adipocytes. Endocr Rev 25:177–204.
  • Way JM, Gorgun CZ, Tong G, Uysal KT, Brown KK, Harrington WW, Oliver Jr., WR, Willson TM, Kliewet SA, Hotamistigli GS. 2001. Adipose tissue resistin expression in severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor-g agonist. J Biol Chem 276:25651–25653.
  • Weyer C, Funahashi T, Tanaka S, Hotta S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935.
  • Woods SC, Seeley RJ, Porte Jr, D, Schwartz MW. 1998. Signals that regulate food intake and energy homeostasis. Science 280:1378–1383.
  • Wortley KE, Anderson K, Garcia K, Murray J, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox H, Yancopoulos GD, Wiegand SJ, Sleeman MW. 2004. Deletion of ghrelin reveals on effect on food intake, but a primary role in energy balance. Obes Res 12:170.
  • Wren AM, Seal LJ, Cohan MA, Brynes AE, Frost GS, Murphy KG, Dhille WS, Ghatel MA, Blood SR. 2001. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992–5995.
  • Xu H, Sethi JK, Hotamisligil GS. 1999. Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor1. J Biol Chem 274:26287–26295.
  • Yamauchi T, Kamon I, Waki H, Terauchi Y, Kubota N, Hata Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavlirova O, Vinson CR, Kimura S, Tomita M, Froguel P, Kadowaki T. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946.
  • Yamauchi T, Kammon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hata K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. 2003a. Cloning ofadiponectin receptors that mediate antidiabetic effects. Nature 423:762–769.
  • Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Taketa M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE- deficient mice from atherosclerosis. J Biol Chem 278: 2461–2468.
  • Yang H, Egan JM, Rodgers BD, Bernier M, Montrose-Rafizadeh C. 1999. Differential expression of a novel seven transmembrane domain protein in epididymal fat from aged and diabetic mice. Endocrinology 140:2859–2867.
  • Yang YS, Song HD, Li RY, Zhou LB, Zhu ZD, Hu RM, Han ZG, Chen JL. 2003. The gene expression profiling of human visceral adipose tissue and its secretary functions. Biochem Biophys Res Commun 300:839–846.
  • Yaswen L, Diehl N, Brennan MB, Hochgreschwender U. 1999. Obesity in the mouse model ofpro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Genet 9:1068–1070.
  • Yen TT, Gill AM, Friegeri LG, Batsh GS, Wolff GL. 1994. Obesity, diabetes, and neoplasia in yellow (Ay/a)/- mice: Ectopic expression of the agouti gene. FASEB J 8:479–488.
  • Yokota T, Meka CS, Medina KL, Igarashi H, Comp PC, Takahashi M, Nishida M, Oritani K, Miyagawa J, Funahashi T, Tomiyama Y, Matsuzawa Y, Kincarde PW. 2002. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest 109:1303–1310.
  • Zander M, Madsbad S, Madsen JL, Holst JJ. 2002. Effect of 6-week course of glucagons-like peptide 1 on glycaemic control, insulin sensitivity, and ß cell function in type 2 diabetes: A parallel study. Lancet 359:824–830.
  • Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432.
  • Zhang W, Zhao L, Li TR, Chai B, Fan Y, Gantz I, Mulholland MW. 2004. Inhibition of adipogenesis by ghrelin. Mol Biol Cell 15:2484–2491.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.